| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TACR2 |
| Uniprot No | P21452 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-398aa |
| 氨基酸序列 | MGTCDIVTEANISSGPESNTTGITAFSMPSWQLALWATAYLALVLVAVTGNAIVIWIILAHRRMRTVTNYFIVNLALADLCMAAFNAAFNFVYASHNIWYFGRAFCYFQNLFPITAMFVSIYSMTAIAADRYMAIVHPFQPRLSAPSTKAVIAGIWLVALALASPQCFYSTVTMDQGATKCVVAWPEDSGGKTLLLYHLVVIALIYFLPLAVMFVAYSVIGLTLWRRAVPGHQAHGANLRHLQAMKKFVKTMVLVVLTFAICWLPYHLYFILGSFQEDIYCHKFIQQVYLALFWLAMSSTMYNPIIYCCLNHRFRSGFRLAFRCCPWVTPTKEDKLELTPTTSLSTRVNRCHTKETLFMAGDTAPSEATSGEAGRPQDGSGLWFGYGLLAPTKTHVEI |
| 预测分子量 | 44,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TACR2(速激肽受体2)重组蛋白研究的模拟参考文献示例(注：部分文献信息为假设性概括，实际引用需核对真实文献)：
---
1. **文献名称**: "Recombinant Expression and Functional Characterization of Human TACR2 in Insect Cells"
**作者**: Zhang Y, et al.
**摘要**: 研究利用杆状病毒-昆虫细胞系统高效表达重组人源TACR2蛋白，验证其与配体神经激肽A(NKA)的结合活性，并证实其通过Gq蛋白介导的钙信号通路发挥功能。
2. **文献名称**: "TACR2 Receptor Signaling in Colonic Inflammation: Insights from a Recombinant Protein Model"
**作者**: Gupta S, et al.
**摘要**: 通过重组TACR2蛋白体外实验，揭示了该受体在肠上皮细胞炎症反应中的作用机制，发现其激活可促进IL-8分泌，提示其作为炎症性肠病的潜在治疗靶点。
3. **文献名称**: "Structural Dynamics of TACR2 Revealed by Cryo-EM and Site-Directed Mutagenesis"
**作者**: Wang L, et al.
**摘要**: 利用冷冻电镜解析重组TACR2蛋白的跨膜结构域构象变化，结合点突变实验阐明关键氨基酸残基在配体识别和受体激活中的功能。
4. **文献名称**: "Development of a High-Throughput Screening Assay for TACR2 Antagonists Using Recombinant Receptor Technology"
**作者**: Thompson R, et al.
**摘要**: 建立基于重组TACR2稳定转染细胞系的药物筛选平台，成功鉴定出多个新型小分子拮抗剂，为治疗TACR2相关神经精神疾病提供先导化合物。
---
**提示**：实际研究中建议通过PubMed或Web of Science以“TACR2 recombinant protein”“NK2R expression”等关键词检索最新文献，优先选择近五年内发表的实验性研究。
**Background of TACR2 Recombinant Protein**
TACR2. or tachykinin receptor 2 (also known as neurokinin 2 receptor, NK2R), is a G protein-coupled receptor (GPCR) that binds tachykinin peptides, primarily neurokinin A (NKA). It plays a key role in mediating physiological processes such as smooth muscle contraction, inflammation, pain signaling, and neurotransmission. TACR2 is widely expressed in the central nervous system, gastrointestinal tract, and respiratory system, making it a therapeutic target for disorders like asthma, irritable bowel syndrome, and chronic pain.
Recombinant TACR2 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional receptor proteins for research and drug development. These recombinant proteins retain structural and functional integrity, enabling studies on ligand-receptor interactions, signaling pathways (e.g., IP3/DAG or cAMP pathways), and receptor modulation. Tagged versions (e.g., His-, FLAG-tags) facilitate purification and detection.
In drug discovery, TACR2 recombinant proteins are used to screen antagonists or agonists for treating tachykinin-related diseases. For example, NK2R antagonists have been explored to mitigate bronchoconstriction in asthma or visceral hypersensitivity in gastrointestinal disorders. Structural studies using recombinant TACR2 also aid in understanding receptor activation mechanisms and designing targeted therapies. Challenges include maintaining proper post-translational modifications (e.g., glycosylation) during production, which are critical for ligand binding and receptor function.
Overall, TACR2 recombinant proteins serve as essential tools for unraveling the receptor’s pathophysiology and advancing precision therapeutics.
×
